Drug Type Recombinant polypeptide |
Synonyms XTL6001 |
Target |
Action agonists |
Mechanism GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity | Phase 1 | China | 10 Jun 2025 | |
Chronic Kidney Diseases | IND Approval | China | 01 Jul 2025 | |
Proteinuria | IND Approval | China | 01 Jul 2025 | |
Metabolic Syndrome | IND Application | United States | 01 Dec 2024 | |
Metabolic Syndrome | IND Application | China | 01 Dec 2024 |